Prognosis of Medication-Related Osteonecrosis of the Jaw with Surgical Treatment

In 2014, the American Association of Oral and Maxillofacial Surgery (AAOMS) recommended surgical treatment for medication-related osteonecrosis of the jaw (MRONJ) patients classified as Stage 3. In 2016, the Japanese position paper recommended surgical treatment classified as Stage 2. Some systematic review reported effectiveness of surgical treatment for MRONJ. However there is no concerted consciousness on the treatment methods of MRONJ patients in the present. This study aimed to retrospectively elucidate clinical outcomes of the surgical treatment of MRONJ patients under the same criteria. This study included 86 patients in 40 osteoporosis patients (5 men and 35 women, average age: 78.8 years) and 46 cancer patients (18 men and 28 women, average age: 67.7 years). The outcome was classified into two categories: Healing or No healing in each stage. Among 86 patients, MRONJ was found in 91 jaws, of which 69 jaws (75.8%) were surgically operated. Total healing rate of surgical treatment was 85.5%. and total healing rate of conservative treatment was 4.5%. It was suggested that surgical treatment for MRONJ had a high clinical response rate in all stages.